News

EYLEA HD Injection Shows Promising Three-Year Results

EYLEA HD Injection Shows Promising Three-Year Results

Outstanding Results from EYLEA HD Clinical Trials

Recent data highlights a remarkable achievement in vision improvement and anatomical progress for patients utilizing EYLEA HD (aflibercept) Injection 8 mg. This development follows a three-year extension study of the Phase 3 PHOTON trial, demonstrating sustained benefits for individuals affected by diabetic macular edema.

Longer Dosing Intervals Provide Clinical Benefits

In the latest study results, a substantial 88% of EYLEA HD patients maintained a dosing interval of ?12 weeks at week 156, successfully preserving the visual enhancements and anatomical improvements achieved during the initial 96 weeks. Such findings underscore the efficacy of EYLEA HD, providing patients not only consistency in treatment but also a significant reduction in healthcare visits.

Reduced Fluid Reaccumulation

Patients transitioning to EYLEA HD reported a markedly slower rate of fluid reaccumulation compared to their prior treatment with EYLEA (aflibercept) Injection 2 mg. These results reinforce the notion of EYLEA HD having a longer duration of action, enabling patients to enjoy extended freedom from injections while maintaining their progress.

Safety Profile Remains Stable

Throughout this extensive study, the safety profile of EYLEA HD aligned with previously established data. Consistent findings indicate a tolerable safety margin similar to EYLEA. Noteworthy occurrences of ocular treatment emergent adverse events (TEAEs) were documented, including cataracts and vitreous floaters.

Impact on Diabetic Eye Disease Management

Diana V. Do, M.D., an ophthalmology professor and trial investigator, emphasized the significance of these findings. According to Dr. Do, many patients face the challenge of balancing treatment effectiveness with life obligations, such as work and family commitments. The outcomes from EYLEA HD not only validate its application as a first-line treatment but also offer hope for those battling diabetic eye diseases.

Trial Design and Patient Enrollment

Initially, participants in the PHOTON trial were randomly assigned into groups receiving either 12- or 16-week dosing intervals after three months of initial treatment. During the study, intervals were adjustable based on clinical response, allowing for tailored patient care. The vast majority of EYLEA HD patients who completed the study experienced sustained vision and anatomical improvements.

Collaborative Development with Bayer

EYLEA HD, also known as Eylea™ 8 mg in Europe and Japan, is co-developed by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer AG. While Regeneron holds exclusive rights within the United States, Bayer enjoys the marketing rights internationally, with both companies sharing profits from EYLEA and EYLEA HD sales.

About Diabetic Eye Disease

Diabetic retinopathy (DR) is notable for causing microvascular damage in the retina, primarily stemming from impaired blood sugar regulation in diabetes patients. As the disease progresses, it can lead to severe conditions like proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME), significantly impacting vision. In the United States alone, around 1.5 million adults have been diagnosed with DME, while approximately 6 million experience DR without DME.

Regeneron’s Commitment to Eye Care Innovations

At Regeneron, innovation drives our endeavors as we develop groundbreaking therapies to improve eye health for countless individuals. EYLEA's advent revolutionized clinical practices within retinal disease treatment, emphasizing the importance of extensive research and patient care strategies. Our ongoing commitment remains steadfast in delivering effective treatments for conditions such as diabetic eye diseases.

Frequently Asked Questions

What is EYLEA HD?

EYLEA HD (aflibercept) Injection 8 mg is a treatment for diabetic macular edema, designed to provide long-lasting visual and anatomical benefits with fewer injections.

How long did the study on EYLEA HD last?

The extension study of the Phase 3 PHOTON trial lasted three years, with significant results reported at 156 weeks.

What were the primary outcomes of the trial?

The study revealed that patients sustained visual and anatomical improvements while achieving longer dosing intervals with EYLEA HD.

What is the safety profile of EYLEA HD?

The safety profile is consistent with EYLEA's established data, with no significant new safety concerns raised during the trial.

How is EYLEA HD administered?

EYLEA HD is administered as an injection into the eye, typically requiring three or four injections per year depending on patient response.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 144

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 0

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 90

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 43

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 118

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 21

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 151

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 96

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 40

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading

Top 5 Most Recently Viewed Articles

Redwire Corp's Exciting NASA Contract Boosts RDW Stock

Updated Category News Views 291

Recent Developments with Redwire Corp (RDW) Redwire Corp shares have recently experienced a notable increase following the announcement of a new contract with NASA. This contract marks an exciting milestone for the company as it seeks to enhance its role in space exploration and biotechnology. Details of the NASA Contract Redwire has been awarded an...

Continue Reading
Exploring the RWA Tokenization and Its Financial Impact

Updated Category News Views 442

CoinEx Research Explores the Evolution of RWA Tokenization CoinEx Research, part of the prominent crypto exchange CoinEx, has launched an insightful two-part report titled “Unlocking the On-Chain Asset Era: A Deep Dive into the Real World Asset (RWA) Tokenization Revolution.” This comprehensive analysis ventures deep into the burgeoning landscape of RWAs, exploring...

Continue Reading
Transforming $1000 into Nearly $10,000: RJF's Growth Journey

Updated Category News Views 213

Unveiling the Growth of Raymond James Financial Inc. Investors often look for robust opportunities that can yield significant returns over time. Raymond James Financial Inc. (NYSE: RJF) has proven to be one such opportunity. Over the past 20 years, RJF has consistently outperformed the market, generating a remarkable average annual return of 12.05%. With a current market...

Continue Reading
Aequum Capital Unlocks $250 Million Financing for Expansion

Updated Category News Views 193

Aequum Capital Unlocks $250 Million Financing for Expansion Aequum Capital Financial, LLC, a rapidly growing specialty finance lender backed by Castlelake, L.P., recently announced a groundbreaking achievement. The company has successfully closed a $250 million debt facility in collaboration with Wells Fargo & Company (NYSE: WFC). This pivotal financing marks a...

Continue Reading
Market Insights: DAX and USD/JPY Trends Worth Noticing

Updated Category News Views 176

Focus on DAX Amid Economic Stagnation The DAX index is currently navigating through a steady phase amid stagnant economic signals. Its performance is largely affected by anticipation regarding upcoming U.S. economic data and evolving conditions within Germany's economy. Stagnation in German GDP Recently, German GDP has shown no growth, remaining at 0% quarter-on-quarter....

Continue Reading